Dr. Yannis Paulus | Medical and Surgical Retina
Why It Matters
Advances in AI, imaging, and nanotherapeutics pioneered by Dr. Paulus could deliver durable, personalized treatments for prevalent retinal diseases, reducing vision loss and setting new industry benchmarks.
Key Takeaways
- •Dr. Paulus treats patients like family, emphasizing personalized care.
- •Focus on retinal diseases: macular degeneration, diabetic retinopathy, eye strokes.
- •Lab develops nanotech, AI, imaging, photonics for lasting therapies.
- •Over 20 years experience, integrates cutting‑edge tech into clinical practice.
- •Collaboration at Johns Hopkins drives innovative treatments and research breakthroughs.
Summary
Dr. Yannis Paulus, the Jonas Freedom Professor of Ophthalmology and Biomedical Engineering at Johns Hopkins, heads a multidisciplinary retina program that treats macular degeneration, diabetic retinopathy, retinal vein and artery occlusions, and other sight‑threatening conditions. He emphasizes a family‑like, patient‑centered approach, promising to guide each individual through personalized treatment plans.
His laboratory focuses on high‑impact technologies—nanotechnology for sustained drug delivery, artificial‑intelligence‑driven imaging, advanced photonics and laser platforms—to address clinical gaps where existing therapies fall short. By marrying basic research with bedside care, the team aims to create longer‑lasting, minimally invasive solutions for diseases that currently lack effective options.
Paulus repeatedly stresses, “I will be with you each step of the way,” underscoring his commitment to transparent, lifestyle‑compatible care. He describes the retina as a “window into the body,” illustrating how retinal health reflects systemic disease and why restoring vision can profoundly change patients’ lives.
The work positions Johns Hopkins at the forefront of retinal innovation, promising faster adoption of AI‑enhanced diagnostics and nanomedicine‑based treatments. If successful, these advances could dramatically improve outcomes for millions suffering from age‑related macular degeneration and diabetic eye disease, reshaping standards of care across ophthalmology.
Comments
Want to join the conversation?
Loading comments...